Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 3/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28201368 | 0.86 | LMNA (0.39) | LMNAHTR6GNAI3CXCR4SIGMAR1 | |
| SCHEMBL18064813 | 0.82 | ALDH1A1 (0.42) | LMNAKMT2ASLC6A2SLC6A4 | |
| SCHEMBL18064812 | 0.82 | ALDH1A1 (0.42) | LMNAKMT2ASLC6A2SLC6A4 | |
| SCHEMBL23349177 | 0.78 | MGLL (0.42) | LMNA | |
| SCHEMBL18064943 | 0.78 | MGLL (0.42) | LMNA | |
| SCHEMBL18064753 | 0.77 | LMNA (0.39) | LMNAHTR6CXCR4HTR2CHTR2B | |
| SCHEMBL18087118 | 0.75 | MGLL (0.57) | — | |
| SCHEMBL23348977 | 0.75 | MGLL (0.57) | — | |
| SCHEMBL18064885 | 0.74 | LMNA (0.48) | LMNAACHEHTR6C5AR1KMT2A | |
| SCHEMBL3962172 | 0.71 | LMNA (0.73) | LMNAACHEHTR6CXCR4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107660199-B | Piperazine carbamates and methods of making and using the same | H.隆德贝克有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-3271352-B1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2021-05-12 | — | — | EP | disclosed |
| EP-3271352-B1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2021-05-12 | — | — | EP | disclosed |
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| CN-107660199-A | Piperazine carbamate and its preparation and application | 阿比德治疗公司 | 2018-02-02 | — | — | CN | disclosed |
| EP-3271352-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160272602-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| WO-2016149401-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016149401-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272602-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | LMNA 4625/4885ACHE 85/4885HTR6 133/4885 |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | LMNA 4625/4885ACHE 85/4885HTR6 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.